UniProtKB/Swiss-Prot P07814: Variant p.Pro893His

Bifunctional glutamate/proline--tRNA ligase
Gene: EPRS1
Feedback?

Variant information Variant position:

893 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Proline (P) to Histidine (H) at position 893 (P893H, p.Pro893His). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and hydrophobic (P) to medium size and polar (H) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs5030751 [ dbSNP | Ensembl ]

Sequence information Variant position:

893 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

1512 The length of the canonical sequence.
Location on the sequence:

IPGQPPLSQSSDSSPTRNSE P AGLETPEAKVLFDKVASQGE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         IPGQ---PPLSQSSDSSPTRNSEPAGLETPEAKVLFDKVASQGE

Mouse                         VPGQ---PPASQNSHSNPVSNAQPAGAEKPEAKVLFDRVAC

Drosophila                    KPGTTAPAPAAAPVKVKQEKNPDPASVLT--VNTLLNKIAQ

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 1512	Bifunctional glutamate/proline--tRNA ligase
Region	760 – 956	3 X 57 AA approximate repeats
Region	869 – 900	Disordered
Compositional bias	875 – 893	Polar residues
Modified residue	882 – 882	Phosphoserine
Modified residue	885 – 885	Phosphoserine
Modified residue	886 – 886	Phosphoserine; by CDK5
Modified residue	891 – 891	Phosphoserine
Modified residue	898 – 898	Phosphothreonine
Mutagenesis	886 – 886	S -> A. Abolishes release from the aminoacyl-tRNA synthetase multienzyme complex and association with the GAIT complex upon interferon-gamma treatment. Abolishes interaction with SYNCRIP.
Mutagenesis	886 – 886	S -> D. Not active in translation inhibition (phosphomimetic) and abolishes GAIT complex association with eiF4G. No effect on interaction with SYNCRIP.

Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.